Physician profile
Fernando Torres
NPI 1205856366
$60,857.33
in general payments reported to CMS, 2019-2025
24 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $5,901 · 2021: $5,608 · 2022: $6,756 · 2023: $7,625 · 2024: $2,344 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,831 · Consulting Fee: $4,111 · Travel and Lodging: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,831.35 |
| Consulting Fee | $4,111.25 |
| Travel and Lodging | $958.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $26,718.41 | 2019-2025 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $23,934.09 | 2019-2022 | |
| Kamada LTD. | $4,674.51 | 2023-2025 | |
| Glaxosmithkline, LLC. | $1,819.63 | 2024-2025 | Arexvy, Nucala |
| Paratek Pharmaceuticals, INC. | $1,680.00 | 2021 | |
| La Jolla Pharmaceutical Company | $464.31 | 2022-2024 | Giapreza |
| Polarean, INC. | $343.65 | 2025 | Xenoview |
| Sandoz INC. | $310.70 | 2019-2023 | Treprostinil |
| Actelion Pharmaceuticals US, INC. | $213.71 | 2023-2025 | Uptravi, Opsumit, Bosentan |
| Genentech USA, INC. | $139.99 | 2019 | |
| Paragonix Technologies, INC. | $122.31 | 2024 | Pancreaspak, Sherpapak, Lungguard |
| Genentech, INC. | $107.31 | 2021 | |
| Adma Biomanufacturing LLC | $102.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.12 | 2019-2023 | Ofev |
| Inari Medical, INC. | $39.85 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $23.13 | 2024 | Prolastin-C Liquid |
| Insmed, INC. | $21.17 | 2019 | |
| Baxter Healthcare | $19.65 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $17.78 | 2024 | Dupixent |
| Amgen INC. | $16.51 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $16.03 | 2023 | Glassia |
| Merck Sharp & Dohme LLC | $13.58 | 2019 | |
| Lundbeck LLC | $11.75 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.